Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
Status:
Recruiting
Trial end date:
2032-09-25
Target enrollment:
Participant gender:
Summary
TAPISTRY is a Phase II, global, multicenter, open-label, multi-cohort study designed to
evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or
in rational, specified combinations in participants with unresectable, locally advanced or
metastatic solid tumors determined to harbor specific oncogenic genomic alterations or who
are tumor mutational burden (TMB)-high as identified by a validated next-generation
sequencing (NGS) assay. Participants with solid tumors will be treated with a drug or drug
regimen tailored to their NGS assay results at screening. Participants will be assigned to
the appropriate cohort based on their genetic alteration(s). Treatment will be assigned on
the basis of relevant oncogenotype, will have cohort-specific inclusion/exclusion criteria,
and, unless otherwise specified, will continue until disease progression, loss of clinical
benefit, unacceptable toxicity, participant or physician decision to discontinue, or death,
whichever occurs first.